Lonza, Stipple Bio Partner on Precision Cancer ADCs
Lonza and Stipple Bio have entered into a multi-target licensing agreement aimed at accelerating the development of next-generation antibody-drug conjugate (ADC) therapies for cancer,…
Read More...
Read More...
